Belite Bio, Inc (BLTE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
147.03 USD
-2.30
(-1.540%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 147.03 |
Hot Take ↕ | July 11, 2026, 6:33 a.m. EDT
The short-term outlook remains neutral despite recent volatility, as the stock trades near its 50-day average with no clear momentum breakout. While the price recently rallied from mid-June highs, the latest session closed lower, and the statistical forecast model offers virtually no directional edge, suggesting the immediate path is choppy rather than trending. Long-term, the business shows a mixed picture: while the three-year cumulative return is positive (+56%), the journey was brutal, featuring a nearly 70% crash in 2023 followed by a massive recovery. However, the most recent annual period ended on a positive note, avoiding the severe multi-year decline penalty that would otherwise drag the rating down. Despite the recovery, the fundamentals remain precarious with negative earnings, a forward P/E of 158x, and no analyst consensus, indicating the market views this as a high-risk speculative play rather than a solid investment. There is no dividend to provide income or cushion against further downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.137995 |
| MSTL | 0.154453 |
| MSTL_66 | 0.157756 |
| AutoTheta | 0.170033 |
| AutoARIMA | 0.223548 |
| MSTL_96 | 0.243881 |
| MSTL_66_96 | 0.251136 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 3.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.371 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 5,893,710,848 |
| Forward P/E | 155.70 |
| Beta | -1.23 |
| Website | https://www.belitebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3486946 |
| Address1 | 12,750 High Bluff Drive |
| Address2 | Suite 475 |
| All Time High | 200.0 |
| All Time Low | 8.8 |
| Ask | 188.1 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 216,600 |
| Average Daily Volume3 Month | 190,824 |
| Average Volume | 190,824 |
| Average Volume10Days | 216,600 |
| Beta | -1.234 |
| Bid | 106.51 |
| Bid Size | 2 |
| Book Value | 20.228 |
| City | San Diego |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 147.03 |
| Current Ratio | 33.706 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 154.16 |
| Day Low | 145.65 |
| Display Name | Belite Bio |
| Earnings Call Timestamp End | 1,779,309,000 |
| Earnings Call Timestamp Start | 1,779,309,000 |
| Earnings Timestamp | 1,779,280,200 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -101,187,000 |
| Ebitda Margins | 0.0 |
| Eps Current Year | -3.28429 |
| Eps Forward | 0.94429 |
| Eps Trailing Twelve Months | -2.54 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 147.2889 |
| Fifty Day Average Change | -0.25889587 |
| Fifty Day Average Change Percent | -0.001757742 |
| Fifty Two Week Change Percent | 134.86946 |
| Fifty Two Week High | 200.0 |
| Fifty Two Week High Change | -52.97 |
| Fifty Two Week High Change Percent | -0.26485002 |
| Fifty Two Week Low | 59.12 |
| Fifty Two Week Low Change | 87.91 |
| Fifty Two Week Low Change Percent | 1.4869758 |
| Fifty Two Week Range | 59.12 - 200.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,651,239,000,000 |
| Float Shares | 18,459,883 |
| Forward Eps | 0.94429 |
| Forward P E | 155.70428 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.44268 |
| Held Percent Institutions | 0.23648001 |
| Implied Shares Outstanding | 40,085,091 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. |
| Long Name | Belite Bio, Inc |
| Market | us_market |
| Market Cap | 5,893,710,848 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1776217412 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -90,272,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,985,906,639 |
| Number Of Analyst Opinions | 8 |
| Open | 148.36 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 246 6240 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 147.03 |
| Post Market Time | 1,783,976,617 |
| Previous Close | 149.33 |
| Price Eps Current Year | -44.767666 |
| Price Hint | 2 |
| Price To Book | 7.268637 |
| Profit Margins | 0.0 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -2.3 |
| Regular Market Change Percent | -1.54021 |
| Regular Market Day High | 154.16 |
| Regular Market Day Low | 145.65 |
| Regular Market Day Range | 145.65 - 154.16 |
| Regular Market Open | 148.36 |
| Regular Market Previous Close | 149.33 |
| Regular Market Price | 147.03 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 189,151 |
| Return On Assets | -0.12991 |
| Return On Equity | -0.18927999 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 40,085,091 |
| Shares Percent Shares Out | 0.0328 |
| Shares Short | 1,314,142 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,201,317 |
| Short Name | Belite Bio, Inc |
| Short Percent Of Float | 0.0631 |
| Short Ratio | 5.37 |
| Source Interval | 15 |
| State | CA |
| Symbol | BLTE |
| Target High Price | 266.0 |
| Target Low Price | 185.0 |
| Target Mean Price | 210.5 |
| Target Median Price | 200.5 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.54 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 144.12158 |
| Two Hundred Day Average Change | 2.9084167 |
| Two Hundred Day Average Change Percent | 0.0201803 |
| Type Disp | Equity |
| Volume | 189,151 |
| Website | https://www.belitebio.com |
| Zip | 92,130 |